Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT01027923
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00998049
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 36
- Registration Number
- NCT00990054
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00943943
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 39
- Registration Number
- NCT00906945
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00903968
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cape Cod Hospital, Hyannis, Massachusetts, United States
🇺🇸Newton-Wellesley Hospital, Newton, Massachusetts, United States
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00822770
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
- Conditions
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 178
- Registration Number
- NCT00741325
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
- Conditions
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 164
- Registration Number
- NCT00741780
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00720603
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.